Phantomics and Severance Cardiovascular Hospital Expand AI Collaboration for Cardiovascular Disease

Phantomics Inc., a medical imaging AI company, signed a memorandum of understanding (MOU) with Severance Cardiovascular Hospital on April 11 for AI research and technology development. The signing ceremony was attended by Seok-Min Kang, Director of Severance Cardiovascular Hospital, co-CEOs Byoung Wook Choi and Pan Ki Kim of Phantomics, and key representatives from both organizations, who held in-depth discussions on future cooperation.
Through the strategic partnership, the two parties will carry out multifaceted joint research to strengthen the clinical utility of Myomics®, Phantomics' AI-based cardiac MRI analysis solution that is drawing attention in the global market, and Angiomics®, its cardiac CT analysis solution, and to increase their practical use in clinical settings. In particular, they plan to focus on developing heart-disease prediction models using the hospital's extensive clinical data and on advancing algorithms to improve AI diagnostic accuracy.
Myomics applies state-of-the-art deep learning to dramatically reduce cardiac MRI analysis time, which demands a high level of expertise, from more than 30 minutes to under five minutes while delivering cardiac function and tissue analysis results with over 95% accuracy. This enables rapid and precise diagnosis of a wide range of heart conditions, including heart failure, myocardial infarction, myocarditis and amyloidosis, and is expected to contribute to the diagnosis of rare heart diseases that are difficult to detect early.
Both parties expect that this innovation will not only maximize diagnostic efficiency for clinicians but also allow patients to receive results on the day of their examination, minimizing unnecessary return visits and treatment delays and thereby improving the quality of care and patient satisfaction.
Severance Cardiovascular Hospital, opened in 1991 as Korea's first specialized hospital for heart and vascular disease, is the only medical institution in Korea to have performed more than 30,000 arrhythmia procedures. It was named an outstanding hospital in the cardiovascular field in Newsweek's World's Best Hospitals 2022 and holds internationally recognized clinical capabilities, including Korea's first successful heart transplant and leadership in cardiovascular intervention and heart-valve treatment.
"It is very meaningful for Phantomics, which leads global innovation in medical imaging AI, to form a deep partnership with Severance Cardiovascular Hospital, Korea's most prestigious cardiovascular institution," said Pan Ki Kim, CEO of Phantomics. "Through this agreement we hope to solidify and popularize the clinical value of AI-based cardiac diagnosis and ultimately help save patients' lives and improve their quality of life."
"We are pleased to take an important step in actively bringing advanced AI technology into clinical practice to overcome the ever-increasing burden of cardiovascular disease," said Director Seok-Min Kang. "We will work closely so that the synergy between Severance's rich clinical data and expert know-how and Phantomics' innovative AI technology makes a real contribution to earlier diagnosis and better survival for heart-disease patients."
Myomics is currently in active use at more than 20 tertiary hospitals in Korea and at medical institutions in major Asian countries including Japan, Taiwan, Singapore and Thailand, as well as in some European countries, and the company is actively pursuing entry into the North American market. Phantomics has also been recognized on the global stage for its technology and innovation with the CES Innovation Award and the FIX Innovation Awards Grand Prize. The two parties plan to hold regular joint research seminars and technology-exchange meetings and to continue academic cooperation, including publishing papers based on real clinical cases and jointly participating in international conferences.
Phantomics is a medical AI company founded in 2019 by a professor of radiology at Yonsei University Severance Hospital and an imaging physicist with the goal of overcoming cardiovascular disease. Its flagship products, the automated cardiac MRI analysis software Myomics® and the automated cardiac CT analysis software Angiomics®, have obtained medical device approvals from Korea's MFDS, the U.S. FDA, Taiwan, Thailand and Malaysia. They are used clinically at more than 20 general hospitals in Korea, and the company won a CES 2024 Innovation Award in the digital health category. In 2024 it established a U.S. subsidiary in Boston to accelerate its global expansion.